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ABSTRACT
Proton pump inhibitors (PPI) has been widely used by clinicians to treat diseases that require suppression 
of gastric acid. PPI work by inhibiting the proton pump in gastric parietal cells.In adult patients, PPI has 
been widely studied and showed effective results and safe. This result make PPI positioning as the first choice 
medicine in the treatment of diseases that require suppression of gastric acid. As the primary choice therapy, 
PPI administration has been increased not only in adults but also in children. 
PPI is often administered to children with a diagnosis of gastroesophageal reflux disease (GERD) which 
defined as symptoms or complications caused by gastroesophageal reflux (GER). GERD diagnosis in children 
is quite difficult, so it is common to find that diagnosis is established only by the basis of clinical symptoms, 
resulting in overdiagnosis and over-treatment of GERD. The use of PPI in children still needs further study and 
can not be inferred based on adult studies. Inappropropriate PPI prescription without indication will increase 
side effect, risk and also harm the children. Thus, it is important to know the indications, side effects and safety 
of PPI therapy in children.
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ABSTRAK
Penghambat pompa proton (PPP) telah banyak digunakan oleh klinisi untuk mengobati penyakit yang 
membutuhkan supresi asam lambung. PPP bekerja dengan cara menghambat pompa proton pada sel parietal 
lambung. PPP sudah banyak diteliti pada dewasa dan menunjukan hasil yang efektif dan aman. Hasil ini membuat 
PPP menjadi pilihan utama pada penyakit yang memerlukan supresi asam lambung. Terapi PPP sebagai pilihan 
utama telah meningkatkan pemberian PPP tidak hanya pada dewasa tetapi juga pada anak.
PPP sering diberikan kepada anak dengan diagnosis penyakit refluks gastroesofagus (PRGE) yang 
didefinisikan sebagai gejala atau komplikasi yang diakibatkan oleh refluks gastroesofagus (RGE). Diagnosis 
PRGE pada anak cukup sulit, sehingga tidak jarang diagnosis ditegakkan hanya berdasarkan gejala klinis 
yang berujung pada overdiagnosis dan over-treatment PRGE. Penggunaan PPP pada anak masih memerlukan 
penelitian lebih lanjut dan tidak dapat disimpulkan berdasarkan penelitian pada dewasa. Pemberian PPP yang 
tidak sesuai indikasi akan meningkatkan resiko terjadinya efek samping dan dapat membahayakan. Melihat hal 
ini maka penting untuk mengetahui indikasi, efek samping dan keamanan terapi PPP pada anak.
Kata kunci: penghambat pompa proton, anak, penyakit refluks gastroesofagus
INTRODUCTION
Proton pump inhibitors (PPI) have been prescribed 
many times since 1999 and also increased in children 
rapidly.1-5 PPI are drugs that used to suppress acid 
production by inhibiting proton pump in parietal cell. 
PPI therapy has been widely studied in adult, and 
showed that PPI has good efficacy and safety in the 
treatment of diseases that require suppression of acid 
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production.6-9 However, PPI therapy in children led to 
many debate related to the indications, characteristics 
of children who benefit from PPI therapy, the efficacy, 
and safety in children.
PPI is often given to children as empirical therapy 
or before gastroesophageal reflux disease (GERD) 
diagnosis is confirmed. Diagnosis most often based on 
clinical symptom such as refusing to eat, unexplained 
crying, irritable, or regurgitation.10,11 Unexplained 
crying or irritability are the most common symptoms 
that clinician took as the basis to diagnosis GERD 
and prescribe PPI, even though these have made 
overdiagnosis of GERD in children.4,5 There is no 
proof that unexplained crying in children is caused by 
pain in abdomen or any part of their body; it is likely 
a phenomenon of normal development in children. 
Many gastrointestinal symptoms are not caused by 
gastroesophageal reflux (GER) but other disease or 
cause such as sensitivity to milk or dietary protein, 
urinary tract infection or other infection.4,5
Diagnosing GERD or prescribing PPI to children 
is the last thing to do, rather clinician should take 
complete history of children, discussing behavioural 
and dietary consumption, giving explanation and 
reassurace to caregiver or parents before prescribing 
PPI even those thing are time consuming. Children with 
benign and self resolving symptom such as spitting up, 
regurgitation, or unexplained crying in a heathy infant 
cannot be easily diagnose as GERD and do not warrant 
PPI as a therapy.5 Seeing this, empirical therapy of PPI 
can’t be easily justified if not based on careful diagnosis 
and consideration because PPI itself has side effect. If 
PPI is not clinically proven effective in children then it 
shouldn’t be given.11 This review tend to explain GERD 
in children as a diagnosis and which children will be 
having benefit from PPI therapy, also the benefit and 
risk of prescribing PPI in children.
GASTROESOPHAGEAL REFLUX DISEASE
Gastroesophageal reflux disease (GERD) is defined 
when gastroesophageal reflux (GER) cause reflux 
symptoms and complications. Gastroesophageal 
reflux itself is defined as passive movement of gastric 
content into esophagus involuntarly.12-16 GERD is often 
encountered in infant and children. A study in 2009 at 
United States showed a prevalence of 12.4% in infants 
and 1% in the other pediatric age group.17 GER is not 
a pathologic processes when there is no disturbing 
symptoms or complication.12-16 A multicenter study 
conducted in children aged 3-17 years showed the 
prevalence of GER symptoms was 1.8-7.2% in children 
aged 3-9 years and 5-8.2% in children aged 10-17 
years, but another study said that it was difficult to 
measure GER prevalence accurately.16,18
Study in Indonesia conducted by Hegar et al showed 
regurgitation peak occurred at 4 months of age (68.6%) 
and decreased (35.7%) at the age of 4-8 months. The 
study also stated that the Indonesian infants rarely 
experienced regurgitation more than four times a day 
after 8 months of age. Further study in Indonesia by 
Hegar et al showed that regurgitation occurs after the 
age of 6 months will drop significantly in the next 3 
months. This study also stated that GERD is a rare 
occurrence and it is supported by the findings that only 
1/137 infants were diagnosed with GERD.19,20
Table 1. Symptom and sign that maybe associated with 
gastroesophageal reflux10
Symptoms Signs
Recurrent regurgitation with/
without vomitting
Weight loss or poor weight gain
Irritability in infants
Ruminative behaviour
Heartburn or chest pain
Hematemesis
Dysphagia, odynophagia
Wheezing
Stridor
Cough
Hoarseness
Esophagitis
Esophageal stricture
Barrett’s esophagus
Laryngeal/pharyngeal 
inflammation
Recurrent pneumonia
Anemia
Dental erosion
Feeding refusal
Dystonic neck posturing 
(Sandifer syndrome)
Apnea spells
Apparent life-threatening events
Excellent history taking and physical examination 
must be done before we do a diagnostic test especially 
an invasive one such as endoscopy and biopsy was 
done. Complete history will help in diagnosis process 
and therapy. GERD symptoms and signs are important 
thing we must know as a clinician because these are 
the entry point to diagnose children with GERD as 
we can see in Table 1. When children with GERD 
symptoms and signs have a warning sign (Table 2), then 
a complete work up and differential diagnosis must be 
done. After the diagnosis is confirmed, therapy can be 
administered to the children without delay.10
Diagnosing GERD is often difficult because 
there is no golden standard and many patients 
received therapy empirically before the diagnosis is 
confirmed.10,11 GERD is often diagnosed based solely 
on the present of disturbing clinical symptoms in 
children.10,11 Examination to support GERD diagnosis 
such as endoscopy and pH monitoring showed poor 
sensitivity.10,11 Histopathology examination also has poor 
correlation with endoscopy and severity of the symptom. 
There are 2 studies that prove these, study by Vieira et 
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gastrin secretion. Gastrin is a potent stimulator of the 
activation of proton pumps. PPI should be given 1 hour 
before meals to be absorbed and not eliminated by the 
time the proton pump is activated.6-9,28
Gastric acid secretion remained inhibited for a long 
time even though the PPI has been eliminated from 
the circulation. PPI is a weak base and acid labile 
so it should be given in the form of enteric coating 
to prevent degradation by stomach acid and allow 
absorption in the small intestine that have more alkaline 
environment. PPI is not a dose dependent drug.6-9,28
PPI is metabolized by cytochrom P450 with 
enzymes CYP2C19 and CYP3A4. Both of these 
enzymes play a major role in the metabolism of 
PPI especially CYP2C19. The enzymes activity are 
immature at birth and reach adult activity at the age of 
6-12 months after birth. If there is a genetic disorder 
such as CYP2C19 polymorphisms, the enzymes 
activity is decreased and PPI clearance will be impaired 
then the effect of PPI will be prolonged. Liver disorders 
also cause clearance impairment of PPI because both 
of the enzymes are predominantly presence in the 
liver. Long-term PPI therapy has not cause cancer or 
significant abnormality in pediatric.6,9,29
PROTON PUMP INHIBITOR IN CHILDREN
Prescribing PPI in children continue to rise and this 
is supported by evident from the data in the US that 
showed an increase in PPI prescription in children by 
7 fold in the span of 6 years (1999-2004) and one PPI 
drugs prescription with liquid preparations increased 
16 fold. In addition to the increasing use of PPI, another 
study showed that approximately 50% of children 
before the age of 4 months get it and we should see the 
fact before that PPI metabolism enzymes mature at the 
age of 6-12 months after birth. Theoretically, the PPI 
clearance in 50% of children who received PPI therapy 
before 4 months had a higher risk of toxicity. Seeing 
this fact, many infants and children get PPI therapy and 
the prescribing should be based on data that supported 
by research evidence without forgetting the risks and 
benefits of therapy.1-5
Consensus and guideline by NASPGHAN/
EPSGHAN showed that the administration of empirical 
therapy can be tolerated as long as 2-4 weeks in older 
children and adolescents. This empirical therapy 
could also act as a means of diagnostic.10 However, 
empirical PPI therapy is not recommended to be 
given to infants and younger children with GERD 
symptoms, unexplained crying, refuse to eat, irritable 
and regurgitation.10,11 PPI can be given to infants and 
al in Brazil and Genta et al in US show that although 
there is an abnormality on endoscopy does not mean 
there is always also histopathology abnormality and 
otherwise.23,24 Despite of its poor sensitivity, endoscopy 
with Los Angeles (LA) Classification is commonly used 
to aid the diagnosis of GERD in pediatric.10
Many studies try to develop questionnaire, the 
questionnaire purpose is to quantify the GERD 
symptom that will help clinician to diagnose GERD. 
Some of the questionnaire are infant gastroesophageal 
reflux questionnaire (I-GERQ) by Orenstein in 1996, 
I-GERQ revised (I-GERQ-R) as the revision from 
I-GERQ by Kleinman in 2006 and the latest pediatric 
gastroesophageal reflux disease symptom and quality 
of life questionnaire (PGSQ-Cp) by Kleinman in 
2011.27 These developed questionnaires also have 
poor sensitivity and for PGSQ-Cp still need further 
study.10,25-27 Therefore, although the diagnosis of GERD 
is a difficult job to do, the disease still need therapy 
and delaying treatment can’t be justified if the child 
need it. However, giving the therapy to soon without 
a proper diagnosis to confirm is not justified either.11
PROTON PUMP INHIBITOR
Proton pump inhibitor (PPI) works by inhibiting the 
H+K +ATPase pump in the gastric parietal cells. PPI 
should be activated to be able to bind with cysteine 
on proton pump with the rate of activation is different 
depending on the structure of each PPI. PPI that binds 
to cysteine  on the pump will form covalent disulfide 
bonds. When bonds are formed the pump is inactivated 
and gastric acid secretion is inhibited reversibly or 
irreversibly. The PPI steady state is achieved within 
3 days after the first dose, because not all the pumps 
are active and blocked on the first dose. PPI should 
be given before meals because meal will induce 
Table 2. Warning signal requring investigation in infants with 
regurgitation or vomitting10
Bilious vomitting
Gastrointestinal bleeding
Hematemesis
Hematochezia
Consistently forceful vomitting
Onset of vomitting after 6 months of life
Failure to thrive
Diarrhea
Constipation
Fever
Lethargy
Hepatospelomegaly
Bulging fontalnelle
Macro/microcephaly
Seizures
Abdominal tenderness or distension
Documented or suspected genetic/metabolic syndrome
Volume 14, Number 3, December 2013 161
Proton Pump Inhibitors Therapy in Children with Gastroesophageal Reflux
adolescents with reflux esophagitis and are superior 
to alleviate symptoms and heal esophagitis compared 
to H2 receptors (H2R) antagonist.9-11 PPI are superior 
compared to the H2R antagonist because PPI able 
to maintain gastric pH at 4 or more, prevent the 
acid secretion triggered by eating, reduce 24-hour 
intragastric volume, there by reducing reflux material 
and facilitate gastric emptying.9-11
PPI therapy in infants and younger children is not 
recommended and this is supported by randomized 
double blind placebo-controlled studies that showed 
PPI therapy and placebo have similar effects on 
symptoms improvement despite the inhibition of 
acid secretion occurred only in the group of PPI. PPI 
therapy is recommended only when the infant has 
reflux esophagitis as GERD complication.10,11,31-33 
Esomeprazole has been reported using in infant.9 
Other PPI which have been reported using in children 
are omeprazole (≥ 1 year), pantoprazole (≥ 5 years), 
lansoprazole (≥ 1 year), rabeprazole (12-17 years). 
Omeprazole and esomeprazole have been reported 
for maintenance therapy of reflux esophagitis in 
children.9-11,30,31
The timing of PPI administrations very important 
to gain maximum efficacy and effectivity, GER 
management guidance for pediatrician from American 
Academy of Pediatric (AAP) recommend to administer 
PPI ideally approximately 30 minutes before meals 
and this must be educated to the parent or patient. This 
recommendation also said that all clinician should 
recognize that the metabolism of PPI in children have 
a shorter half life, necessitating a higher per-kilogram 
dose to achieve a peak serum concentration and area 
under the curve similar to those in adult.32
Eventhough many PPI have been reported using in 
children as the previous statement but AAP guidance 
stated that pantoprazole and dexlansoprazole are not 
indicated for children. PPI dose and formulation are 
different and many children cannot swallow pills or 
capsule. This guidance show the dose required and 
the administration technique: omeprazole (0.7-3.3 mg/
kg/day) sprinkle contents of capsule onto soft foods, 
lansoprazole (0.7-3 mg/kg/day) sprinkle contents of 
capsule onto soft food or select juices, esomeprazole 
(0.7-3.3 mg/kg/day) sprinkle contents of capsule onto 
soft foods and rabeprazole 20 mg daily oral tablet.32
Long-term PPI therapy without confirming the 
diagnosis is not recommended and the use of PPI 
should be given in the smallest effective dose when 
acid secretion suppression is required. Hassal et al 
studied children aged 1-16 years with PPI therapy 
using omeprazole for 21 months to maintain remission 
of reflux esophagitis showed that maintenance dose 
required  are more than half the dose needed for 
healing in 60% patient.33 Many patients only require 
once a day dosing, more dosing are indicated in other 
specific cases.9-11
The largest randomized double-blind placebo-
controlled studying PPI therapy in children by 
Orenstein showed that the symptom improvement of 
PPI administration and placebo in infants with GERD 
symptoms are identical (54%).34 However, the consensus 
of NAPSGHAN/EPSGHAN stated that the study only 
proves that PPI is not beneficial in infants with GERD 
symptoms but not proven that the symptoms are due 
to GERD.10 Systematic review of studies by van der 
Pol showed that the PPI are proven to be ineffective in 
reducing GERD symptoms in infants.11
The debate over the use of the therapy also increased 
because a study suggest that although the use of PPI 
in older children seemed safe and well tolerated, the 
evidence of PPI safety in pediatric is still lacking.11 
Study in PPI therapy with placebo-controlled are also 
lacking.11 There are 5 PPI studies in infants, only 1 
study showed that PPI is more effective compared to 
hydrolyzed formula, 2 studies showed that PPI are 
noteffective and 2 studies showed that PPI are equally 
effective with placebo.34-36,38,39
Van der Pol systematic review also includes 
research in older children and adolescents. The 
results showed that PPI therapy is equally effective in 
adolescents when compared with alginate, ranitidine 
or different dose PPI.11 Adolescents study also found 
mild to moderate side effects in 2 studies.40,41 Reduction 
of gastric acid in infants and children showed that 
PPI are more effective than placebo, alginate or 
ranitidine at 4 studies.35,36,42,43 The interesting thing is 
PPI therapy showed no difference in improvement of 
histopathology parameter compared with ranitidine or 
alginate at 3 studies.42-44 PPI therapy shown to reduce 
GERD symptoms in adolescents and equally effective 
when compared with controls at 2 studies.45,46 This 
systematic review stated that the recommendation in 
2009 for PPI therapy in infants and children is less 
supported by evidence from double-blind randomized 
clinical study with placebo controls. While in older 
children and adolescents, the data or the results are 
taken from research on adult so it should not be use 
as the basis of recommendations in children and 
adolescent.11
PPI therapy in infants and children is still being debated 
due to the lack of clinical research which can support 
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acid to digest food and the absorption of nutrients which 
require stomach acid. Inhibition of gastric acid that 
should not be done is increasing the risk of side effects 
that shouldn’t be occur and also increases the risk of 
impaired growth in children due to acid suppression. 
Long-term use showed the presence of mild histological 
changes but showed no growth of carcinoma and may 
be given when the benefits outweigh the risk.3-5
CONCLUSION
There are a lot of debates on PPI therapy in 
children that require further clinical study to get data 
on efficacy of PPI therapy in children, especially in 
infants and young children. Although it still needs 
further study, data from recent years showed that the 
majority of patients receiving PPI therapy experienced 
more side effect compared with placebo, especially in 
infants. Seeing this, the therapy should be considered 
wisely by taking into account the indication, benefits, 
risks and also side effects. Overdiagnosis and over-
treatment of GERD with PPI must be avoided. Careful 
considerations and clinical experience with the 
professional ethics of physicians, research evidence 
and diagnostic tools can make PPI therapy more 
rational, precise and accurate.
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